Published: March 4, 2026 at 8:31 am
Antiverse, a BioTech developing AI-designed therapeutic antibodies for undruggable disease targets, has closed a Series A round of £7 million.
The Series A funding brings Antiverse’s total capital raised to over $20m and will enable the Cardiff company to scale its discovery platform for pharmaceutical and foundation partners through collaborative programmes.
Antiverse has entered into a research agreement with the Cystic Fibrosis Foundation to design novel antibodies targeting the extracellular region of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a historically difficult target in cystic fibrosis research.